{"transactions":[{"id":2689,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:07.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":253016,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":75.78,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":253016},"source":{"system":"sec-edgar","filing":"0001140361-26-035609","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035609/form4.xml","form_type":"4"}},{"id":2688,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:07.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":357036,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":49.07,"expiration_date":"2034-12-09","underlying":"Common Stock","underlying_shares":357036},"source":{"system":"sec-edgar","filing":"0001140361-26-035609","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035609/form4.xml","form_type":"4"}},{"id":2687,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:07.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":387012,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":387012},"source":{"system":"sec-edgar","filing":"0001140361-26-035609","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035609/form4.xml","form_type":"4"}},{"id":2686,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-03T20:39:07.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":920941,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the \"Merger Agreement\"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the \"Merger Agreement\"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-26-035609","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035609/form4.xml","form_type":"4"}},{"id":710992,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-10T20:00:17.000Z","date":"2026-07-10","kind":"gift","planned":true,"acquired":false,"shares":75046,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund."}],"balance_after":920941,"source":{"system":"sec-edgar","filing":"0001104659-26-082758","document":"tm2620107-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926082758/tm2620107-1_4seq1.xml","form_type":"4"}},{"id":710991,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-10T20:00:17.000Z","date":"2026-07-08","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":133.63,"value":2672600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $133.52 to $133.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":995987,"source":{"system":"sec-edgar","filing":"0001104659-26-082758","document":"tm2620107-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926082758/tm2620107-1_4seq1.xml","form_type":"4"}},{"id":727251,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-25T00:00:37.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":80000,"price":132.54,"value":10603200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.50 to $132.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1015987,"source":{"system":"sec-edgar","filing":"0001104659-26-077426","document":"tm2618514-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926077426/tm2618514-2_4seq1.xml","form_type":"4"}},{"id":728584,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T01:32:23.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":100,"value":2000000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026."}],"balance_after":68606,"source":{"system":"sec-edgar","filing":"0001636282-26-000084","document":"wk-form4_1782264740.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000084/wk-form4_1782264740.xml","form_type":"4"}},{"id":739075,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-12T21:05:08.000Z","date":"2026-06-10","kind":"sale","planned":true,"acquired":false,"shares":614,"price":86.89,"value":53350.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.835 to $87.165, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1095987,"source":{"system":"sec-edgar","filing":"0001104659-26-073567","document":"tm2617750-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926073567/tm2617750-1_4seq1.xml","form_type":"4"}},{"id":739074,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-12T21:05:08.000Z","date":"2026-06-10","kind":"sale","planned":true,"acquired":false,"shares":2305,"price":86.27,"value":198852.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.74 to $86.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1096601,"source":{"system":"sec-edgar","filing":"0001104659-26-073567","document":"tm2617750-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926073567/tm2617750-1_4seq1.xml","form_type":"4"}},{"id":739073,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-12T21:05:08.000Z","date":"2026-06-10","kind":"sale","planned":true,"acquired":false,"shares":1577,"price":85.19,"value":134344.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.71 to $85.665, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1098906,"source":{"system":"sec-edgar","filing":"0001104659-26-073567","document":"tm2617750-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926073567/tm2617750-1_4seq1.xml","form_type":"4"}},{"id":739072,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-12T21:05:08.000Z","date":"2026-06-10","kind":"sale","planned":true,"acquired":false,"shares":1080,"price":84.18,"value":90914.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.595 to $84.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1100483,"source":{"system":"sec-edgar","filing":"0001104659-26-073567","document":"tm2617750-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926073567/tm2617750-1_4seq1.xml","form_type":"4"}},{"id":739071,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-12T21:05:08.000Z","date":"2026-06-10","kind":"sale","planned":true,"acquired":false,"shares":7654,"price":82.78,"value":633598.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.57 to $83.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1101563,"source":{"system":"sec-edgar","filing":"0001104659-26-073567","document":"tm2617750-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926073567/tm2617750-1_4seq1.xml","form_type":"4"}},{"id":739070,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-12T21:05:08.000Z","date":"2026-06-10","kind":"sale","planned":true,"acquired":false,"shares":6770,"price":82.21,"value":556561.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.57 to $82.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1109217,"source":{"system":"sec-edgar","filing":"0001104659-26-073567","document":"tm2617750-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926073567/tm2617750-1_4seq1.xml","form_type":"4"}},{"id":758406,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-29T21:55:47.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":8026,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."}],"balance_after":8026,"derivative":{"exercise_price":72.51,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":8026},"source":{"system":"sec-edgar","filing":"0001636282-26-000067","document":"wk-form4_1780091744.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000067/wk-form4_1780091744.xml","form_type":"4"}},{"id":776500,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-16T00:00:12.000Z","date":"2026-05-13","kind":"sale","planned":true,"acquired":false,"shares":1341,"price":82.58,"value":110739.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.470 to $83.265, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1115987,"source":{"system":"sec-edgar","filing":"0001104659-26-062867","document":"tm2614621-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926062867/tm2614621-1_4seq1.xml","form_type":"4"}},{"id":776499,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-16T00:00:12.000Z","date":"2026-05-13","kind":"sale","planned":true,"acquired":false,"shares":18659,"price":82.05,"value":1530970.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.455 to $82.440, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1117328,"source":{"system":"sec-edgar","filing":"0001104659-26-062867","document":"tm2614621-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926062867/tm2614621-1_4seq1.xml","form_type":"4"}},{"id":786236,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-09T01:31:49.000Z","date":"2026-05-08","kind":"sale","planned":true,"acquired":false,"shares":19269,"price":75.35,"value":1451919.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.15 to $75.71, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":88606,"source":{"system":"sec-edgar","filing":"0001636282-26-000053","document":"wk-form4_1778290306.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000053/wk-form4_1778290306.xml","form_type":"4"}},{"id":786235,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-09T01:31:49.000Z","date":"2026-05-08","kind":"sale","planned":true,"acquired":false,"shares":24814,"price":74.76,"value":1855094.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.15 to $75.14, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":107875,"source":{"system":"sec-edgar","filing":"0001636282-26-000053","document":"wk-form4_1778290306.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000053/wk-form4_1778290306.xml","form_type":"4"}},{"id":786234,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-09T01:31:49.000Z","date":"2026-05-08","kind":"sale","planned":true,"acquired":false,"shares":33513,"price":73.72,"value":2470578.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.15 to $74.14, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":132689,"source":{"system":"sec-edgar","filing":"0001636282-26-000053","document":"wk-form4_1778290306.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000053/wk-form4_1778290306.xml","form_type":"4"}},{"id":786233,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-09T01:31:49.000Z","date":"2026-05-08","kind":"sale","planned":true,"acquired":false,"shares":2404,"price":72.57,"value":174458.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.03 to $73.00, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":166202,"source":{"system":"sec-edgar","filing":"0001636282-26-000053","document":"wk-form4_1778290306.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000053/wk-form4_1778290306.xml","form_type":"4"}},{"id":804257,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-20T20:05:28.000Z","date":"2026-04-16","kind":"exercise","planned":false,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 398,512 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":387012,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001104659-26-045482","document":"tm2612090-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926045482/tm2612090-2_4seq1.xml","form_type":"4"}},{"id":804256,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-20T20:05:28.000Z","date":"2026-04-16","kind":"exercise","planned":false,"acquired":true,"shares":3000,"price":22.86,"value":68580.0,"ownership":{"direct":true},"balance_after":1135987,"source":{"system":"sec-edgar","filing":"0001104659-26-045482","document":"tm2612090-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926045482/tm2612090-2_4seq1.xml","form_type":"4"}},{"id":810111,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-11T00:00:11.000Z","date":"2026-04-08","kind":"sale","planned":true,"acquired":false,"shares":200,"price":85,"value":17000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."}],"balance_after":1132987,"source":{"system":"sec-edgar","filing":"0001104659-26-042155","document":"tm2611503-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926042155/tm2611503-1_4seq1.xml","form_type":"4"}},{"id":810110,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-11T00:00:11.000Z","date":"2026-04-08","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":83.26,"value":166520.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.00 to $83.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1133187,"source":{"system":"sec-edgar","filing":"0001104659-26-042155","document":"tm2611503-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926042155/tm2611503-1_4seq1.xml","form_type":"4"}},{"id":810109,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-11T00:00:11.000Z","date":"2026-04-08","kind":"sale","planned":true,"acquired":false,"shares":17800,"price":82.48,"value":1468144.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.00 to $82.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1135187,"source":{"system":"sec-edgar","filing":"0001104659-26-042155","document":"tm2611503-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926042155/tm2611503-1_4seq1.xml","form_type":"4"}},{"id":843429,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-14T00:00:08.000Z","date":"2026-03-11","kind":"sale","planned":true,"acquired":false,"shares":3418,"price":75.86,"value":259289.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.585 to $76.480, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1152987,"source":{"system":"sec-edgar","filing":"0001104659-26-027802","document":"tm268769-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926027802/tm268769-1_4seq1.xml","form_type":"4"}},{"id":843428,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-14T00:00:08.000Z","date":"2026-03-11","kind":"sale","planned":true,"acquired":false,"shares":8219,"price":74.83,"value":615027.77,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.525 to $75.400, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1156405,"source":{"system":"sec-edgar","filing":"0001104659-26-027802","document":"tm268769-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926027802/tm268769-1_4seq1.xml","form_type":"4"}},{"id":843427,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-14T00:00:08.000Z","date":"2026-03-11","kind":"sale","planned":true,"acquired":false,"shares":8363,"price":74.29,"value":621287.27,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.525 to $74.520, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1164624,"source":{"system":"sec-edgar","filing":"0001104659-26-027802","document":"tm268769-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926027802/tm268769-1_4seq1.xml","form_type":"4"}},{"id":904541,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-14T01:00:15.000Z","date":"2026-02-11","kind":"sale","planned":true,"acquired":false,"shares":955,"price":64.99,"value":62065.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.95 to $65.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1172987,"source":{"system":"sec-edgar","filing":"0001104659-26-015453","document":"tm266326-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926015453/tm266326-1_4seq1.xml","form_type":"4"}},{"id":904540,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-14T01:00:15.000Z","date":"2026-02-11","kind":"sale","planned":true,"acquired":false,"shares":7551,"price":63.73,"value":481225.23,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.33 to $64.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1173942,"source":{"system":"sec-edgar","filing":"0001104659-26-015453","document":"tm266326-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926015453/tm266326-1_4seq1.xml","form_type":"4"}},{"id":904539,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-14T01:00:15.000Z","date":"2026-02-11","kind":"sale","planned":true,"acquired":false,"shares":11494,"price":62.96,"value":723662.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.33 to $63.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1181493,"source":{"system":"sec-edgar","filing":"0001104659-26-015453","document":"tm266326-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926015453/tm266326-1_4seq1.xml","form_type":"4"}},{"id":931963,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-24T02:31:12.000Z","date":"2026-01-21","kind":"other","planned":false,"acquired":true,"shares":63227,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the pro-rata distribution of shares of common stock for no consideration from a limited liability company in which the Reporting Person is a member."}],"balance_after":168606,"source":{"system":"sec-edgar","filing":"0001779990-26-000002","document":"wk-form4_1769221869.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000177999026000002/wk-form4_1769221869.xml","form_type":"4"}},{"id":936702,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-17T01:00:23.000Z","date":"2026-01-14","kind":"sale","planned":true,"acquired":false,"shares":470,"price":83.79,"value":39381.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.73 to $83.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1192987,"source":{"system":"sec-edgar","filing":"0001104659-26-004659","document":"tm263357-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926004659/tm263357-1_4seq1.xml","form_type":"4"}},{"id":936701,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-17T01:00:23.000Z","date":"2026-01-14","kind":"sale","planned":true,"acquired":false,"shares":5386,"price":83.16,"value":447899.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.71 to $83.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1193457,"source":{"system":"sec-edgar","filing":"0001104659-26-004659","document":"tm263357-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926004659/tm263357-1_4seq1.xml","form_type":"4"}},{"id":936700,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-17T01:00:23.000Z","date":"2026-01-14","kind":"sale","planned":true,"acquired":false,"shares":1854,"price":82.41,"value":152788.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.70 to $82.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1198843,"source":{"system":"sec-edgar","filing":"0001104659-26-004659","document":"tm263357-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926004659/tm263357-1_4seq1.xml","form_type":"4"}},{"id":936699,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-17T01:00:23.000Z","date":"2026-01-14","kind":"sale","planned":true,"acquired":false,"shares":2374,"price":81,"value":192294.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.69 to $81.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1200697,"source":{"system":"sec-edgar","filing":"0001104659-26-004659","document":"tm263357-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926004659/tm263357-1_4seq1.xml","form_type":"4"}},{"id":936698,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-17T01:00:23.000Z","date":"2026-01-14","kind":"sale","planned":true,"acquired":false,"shares":8476,"price":79.82,"value":676554.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $79.28 to $80.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1203071,"source":{"system":"sec-edgar","filing":"0001104659-26-004659","document":"tm263357-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926004659/tm263357-1_4seq1.xml","form_type":"4"}},{"id":936697,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-17T01:00:23.000Z","date":"2026-01-14","kind":"sale","planned":true,"acquired":false,"shares":1440,"price":78.64,"value":113241.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $78.16 to $79.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1211547,"source":{"system":"sec-edgar","filing":"0001104659-26-004659","document":"tm263357-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926004659/tm263357-1_4seq1.xml","form_type":"4"}},{"id":945541,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-07T01:01:52.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":253016,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 253,016 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":253016,"derivative":{"exercise_price":75.78,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":253016},"source":{"system":"sec-edgar","filing":"0001104659-26-001484","document":"tm261906-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926001484/tm261906-3_4seq1.xml","form_type":"4"}},{"id":970583,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-13T01:00:11.000Z","date":"2025-12-10","kind":"sale","planned":true,"acquired":false,"shares":560,"price":76.58,"value":42884.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."}],"balance_after":1212987,"source":{"system":"sec-edgar","filing":"0001104659-25-120758","document":"tm2533301-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465925120758/tm2533301-1_4seq1.xml","form_type":"4"}},{"id":970582,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-13T01:00:11.000Z","date":"2025-12-10","kind":"sale","planned":true,"acquired":false,"shares":10005,"price":75.79,"value":758278.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.30 to $76.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1213547,"source":{"system":"sec-edgar","filing":"0001104659-25-120758","document":"tm2533301-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465925120758/tm2533301-1_4seq1.xml","form_type":"4"}},{"id":970581,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-13T01:00:11.000Z","date":"2025-12-10","kind":"sale","planned":true,"acquired":false,"shares":9435,"price":74.88,"value":706492.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.30 to $75.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1223552,"source":{"system":"sec-edgar","filing":"0001104659-25-120758","document":"tm2533301-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465925120758/tm2533301-1_4seq1.xml","form_type":"4"}},{"id":978618,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-06T01:00:16.000Z","date":"2025-12-04","kind":"sale","planned":true,"acquired":false,"shares":40000,"price":75.01,"value":3000400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.00 to $75.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1232987,"source":{"system":"sec-edgar","filing":"0001104659-25-118983","document":"tm2532835-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465925118983/tm2532835-1_4seq1.xml","form_type":"4"}},{"id":999783,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-11-14T01:24:15.000Z","date":"2025-11-13","kind":"sale","planned":true,"acquired":false,"shares":100,"price":64.52,"value":6452.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."}],"balance_after":1272987,"source":{"system":"sec-edgar","filing":"0001104659-25-111626","document":"tm2531267-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465925111626/tm2531267-1_4seq1.xml","form_type":"4"}},{"id":999782,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-11-14T01:24:15.000Z","date":"2025-11-13","kind":"sale","planned":true,"acquired":false,"shares":1786,"price":63.89,"value":114107.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.52 to $64.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1273087,"source":{"system":"sec-edgar","filing":"0001104659-25-111626","document":"tm2531267-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465925111626/tm2531267-1_4seq1.xml","form_type":"4"}},{"id":999781,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-11-14T01:24:15.000Z","date":"2025-11-13","kind":"sale","planned":true,"acquired":false,"shares":14774,"price":63.14,"value":932830.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.50 to $63.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1274873,"source":{"system":"sec-edgar","filing":"0001104659-25-111626","document":"tm2531267-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465925111626/tm2531267-1_4seq1.xml","form_type":"4"}},{"id":999780,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-11-14T01:24:15.000Z","date":"2025-11-13","kind":"sale","planned":true,"acquired":false,"shares":3340,"price":61.93,"value":206846.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.45 to $62.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1289647,"source":{"system":"sec-edgar","filing":"0001104659-25-111626","document":"tm2531267-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465925111626/tm2531267-1_4seq1.xml","form_type":"4"}},{"id":1127181,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T20:35:31.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 25,000 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 29, 2025 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date."}],"balance_after":25000,"derivative":{"exercise_price":15.55,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001636282-25-000065","document":"wk-form4_1748896522.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628225000065/wk-form4_1748896522.xml","form_type":"4"}},{"id":1216755,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-08T01:01:16.000Z","date":"2025-03-05","kind":"sale","planned":true,"acquired":false,"shares":2674,"price":30.62,"value":81877.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.52 to $30.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1292987,"source":{"system":"sec-edgar","filing":"0001104659-25-021861","document":"tm258443-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465925021861/tm258443-2_4seq1.xml","form_type":"4"}},{"id":1216754,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-08T01:01:16.000Z","date":"2025-03-05","kind":"sale","planned":true,"acquired":false,"shares":7326,"price":29.98,"value":219633.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.49 to $30.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1295661,"source":{"system":"sec-edgar","filing":"0001104659-25-021861","document":"tm258443-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465925021861/tm258443-2_4seq1.xml","form_type":"4"}},{"id":1278283,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-08T01:01:10.000Z","date":"2025-02-05","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":40.58,"value":608700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.30 to $40.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1302987,"source":{"system":"sec-edgar","filing":"0001104659-25-010642","document":"tm255633-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465925010642/tm255633-1_4seq1.xml","form_type":"4"}},{"id":1289096,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-01T01:00:12.000Z","date":"2025-01-31","kind":"exercise","planned":false,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 398,512 shares of the Issuer's common stock, one quarter of which vested on December 18, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":390012,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001104659-25-008235","document":"tm255141-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465925008235/tm255141-1_4seq1.xml","form_type":"4"}},{"id":1289095,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-01T01:00:12.000Z","date":"2025-01-31","kind":"exercise","planned":false,"acquired":true,"shares":8500,"price":22.86,"value":194310.0,"ownership":{"direct":true},"balance_after":1317987,"source":{"system":"sec-edgar","filing":"0001104659-25-008235","document":"tm255141-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465925008235/tm255141-1_4seq1.xml","form_type":"4"}},{"id":1303165,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-14T22:16:29.000Z","date":"2025-01-10","kind":"other","planned":false,"acquired":true,"shares":105379,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the pro-rata distribution of shares of common stock for no consideration from a limited liability company in which the Reporting Person is a member."}],"balance_after":105379,"source":{"system":"sec-edgar","filing":"0001636282-25-000002","document":"wk-form4_1736892981.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628225000002/wk-form4_1736892981.xml","form_type":"4"}},{"id":1304861,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-11T01:00:07.000Z","date":"2025-01-08","kind":"sale","planned":true,"acquired":false,"shares":2868,"price":49.38,"value":141621.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.35 to $49.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range"}],"balance_after":1309487,"source":{"system":"sec-edgar","filing":"0001104659-25-002688","document":"tm252859-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465925002688/tm252859-1_4seq1.xml","form_type":"4"}},{"id":1304860,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-11T01:00:07.000Z","date":"2025-01-08","kind":"sale","planned":true,"acquired":false,"shares":12132,"price":48.72,"value":591071.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.20 to $49.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1312355,"source":{"system":"sec-edgar","filing":"0001104659-25-002688","document":"tm252859-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465925002688/tm252859-1_4seq1.xml","form_type":"4"}},{"id":1335007,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-12T01:02:57.000Z","date":"2024-12-09","kind":"grant","planned":false,"acquired":true,"shares":357036,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 357,036 shares of the Issuer's common stock, and will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":357036,"derivative":{"exercise_price":49.07,"expiration_date":"2034-12-09","underlying":"Common Stock","underlying_shares":357036},"source":{"system":"sec-edgar","filing":"0001104659-24-127707","document":"tm2430773-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465924127707/tm2430773-3_4seq1.xml","form_type":"4"}},{"id":1340062,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-12-07T01:01:08.000Z","date":"2024-12-04","kind":"sale","planned":true,"acquired":false,"shares":1672,"price":47.19,"value":78901.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.00 to $47.275, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1324487,"source":{"system":"sec-edgar","filing":"0001104659-24-126394","document":"tm2430233-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465924126394/tm2430233-2_4seq1.xml","form_type":"4"}},{"id":1340061,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-12-07T01:01:08.000Z","date":"2024-12-04","kind":"sale","planned":true,"acquired":false,"shares":13328,"price":46.5,"value":619752.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.00 to $46.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1326159,"source":{"system":"sec-edgar","filing":"0001104659-24-126394","document":"tm2430233-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465924126394/tm2430233-2_4seq1.xml","form_type":"4"}},{"id":1370774,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-11-09T01:01:14.000Z","date":"2024-11-06","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":59.94,"value":59940.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023."}],"balance_after":1339487,"source":{"system":"sec-edgar","filing":"0001104659-24-116024","document":"tm2427837-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465924116024/tm2427837-2_4seq1.xml","form_type":"4"}},{"id":1370773,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-11-09T01:01:14.000Z","date":"2024-11-06","kind":"sale","planned":true,"acquired":false,"shares":14000,"price":59.17,"value":828380.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.69 to $59.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1340487,"source":{"system":"sec-edgar","filing":"0001104659-24-116024","document":"tm2427837-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465924116024/tm2427837-2_4seq1.xml","form_type":"4"}},{"id":1390544,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-10-05T00:01:09.000Z","date":"2024-10-02","kind":"sale","planned":true,"acquired":false,"shares":9712,"price":56.74,"value":551058.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.52 to $57.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1354487,"source":{"system":"sec-edgar","filing":"0001104659-24-106364","document":"tm2425574-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465924106364/tm2425574-2_4seq1.xml","form_type":"4"}},{"id":1390543,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-10-05T00:01:09.000Z","date":"2024-10-02","kind":"sale","planned":true,"acquired":false,"shares":30288,"price":56.07,"value":1698248.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.51 to $56.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1364199,"source":{"system":"sec-edgar","filing":"0001104659-24-106364","document":"tm2425574-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465924106364/tm2425574-2_4seq1.xml","form_type":"4"}},{"id":1412492,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-07T00:02:13.000Z","date":"2024-09-04","kind":"sale","planned":true,"acquired":false,"shares":14359,"price":48.23,"value":692534.57,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.95 to $48.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1394487,"source":{"system":"sec-edgar","filing":"0001104659-24-097866","document":"tm2423502-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465924097866/tm2423502-1_4seq1.xml","form_type":"4"}},{"id":1412491,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-07T00:02:13.000Z","date":"2024-09-04","kind":"sale","planned":true,"acquired":false,"shares":25641,"price":47.28,"value":1212306.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.95 to $47.855, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1408846,"source":{"system":"sec-edgar","filing":"0001104659-24-097866","document":"tm2423502-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465924097866/tm2423502-1_4seq1.xml","form_type":"4"}},{"id":1436638,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-08-10T00:05:12.000Z","date":"2024-08-07","kind":"sale","planned":true,"acquired":false,"shares":100,"price":42.17,"value":4217.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023."}],"balance_after":1434487,"source":{"system":"sec-edgar","filing":"0001104659-24-087939","document":"tm2421174-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465924087939/tm2421174-1_4seq1.xml","form_type":"4"}},{"id":1436637,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-08-10T00:05:12.000Z","date":"2024-08-07","kind":"sale","planned":true,"acquired":false,"shares":7667,"price":41.52,"value":318333.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.15 to $42.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range"}],"balance_after":1434587,"source":{"system":"sec-edgar","filing":"0001104659-24-087939","document":"tm2421174-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465924087939/tm2421174-1_4seq1.xml","form_type":"4"}},{"id":1436636,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-08-10T00:05:12.000Z","date":"2024-08-07","kind":"sale","planned":true,"acquired":false,"shares":32233,"price":40.4,"value":1302213.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1442254,"source":{"system":"sec-edgar","filing":"0001104659-24-087939","document":"tm2421174-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465924087939/tm2421174-1_4seq1.xml","form_type":"4"}},{"id":1445059,"issuer":{"id":88618,"kind":"organization","name":"ARYA Sciences Acquisition Corp IV","symbol":"ARYD"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true}}],"security":"Class B ordinary shares","published_at":"2024-08-01T01:49:31.000Z","date":"2024-07-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) (\"HoldCo\"), Aja Merger Sub 1 (\"Merger Sub 1\"), Aja Merger Sub 2, Inc. (\"Merger Sub 2\") and Adagio Medical, Inc. (\"Adagio\") (the transactions contemplated thereby, the \"Business Combination\"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis."},{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) (\"HoldCo\"), Aja Merger Sub 1 (\"Merger Sub 1\"), Aja Merger Sub 2, Inc. (\"Merger Sub 2\") and Adagio Medical, Inc. (\"Adagio\") (the transactions contemplated thereby, the \"Business Combination\"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) (\"HoldCo\"), Aja Merger Sub 1 (\"Merger Sub 1\"), Aja Merger Sub 2, Inc. (\"Merger Sub 2\") and Adagio Medical, Inc. (\"Adagio\") (the transactions contemplated thereby, the \"Business Combination\"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) (\"HoldCo\"), Aja Merger Sub 1 (\"Merger Sub 1\"), Aja Merger Sub 2, Inc. (\"Merger Sub 2\") and Adagio Medical, Inc. (\"Adagio\") (the transactions contemplated thereby, the \"Business Combination\"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) (\"HoldCo\"), Aja Merger Sub 1 (\"Merger Sub 1\"), Aja Merger Sub 2, Inc. (\"Merger Sub 2\") and Adagio Medical, Inc. (\"Adagio\") (the transactions contemplated thereby, the \"Business Combination\"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis."}],"balance_after":0,"derivative":{"underlying":"Class A ordinary shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001140361-24-035178","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000114036124035178/form4.xml","form_type":"4"}},{"id":1458677,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-07-06T00:01:58.000Z","date":"2024-07-05","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":37.26,"value":558900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.78 to $37.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1474487,"source":{"system":"sec-edgar","filing":"0001104659-24-078135","document":"tm2418983-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465924078135/tm2418983-2_4seq1.xml","form_type":"4"}},{"id":1513785,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-16T20:10:12.000Z","date":"2024-05-14","kind":"grant","planned":false,"acquired":true,"shares":11323,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 11,323 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 14, 2024 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date."}],"balance_after":11323,"derivative":{"exercise_price":39.29,"expiration_date":"2034-05-14","underlying":"Common Stock","underlying_shares":11323},"source":{"system":"sec-edgar","filing":"0000950170-24-061080","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000095017024061080/ownership.xml","form_type":"4"}},{"id":1703101,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-21T01:00:15.000Z","date":"2023-12-18","kind":"grant","planned":false,"acquired":true,"shares":398512,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 398,512 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":398512,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":398512},"source":{"system":"sec-edgar","filing":"0001104659-23-127819","document":"tm2333399-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465923127819/tm2333399-1_4seq1.xml","form_type":"4"}},{"id":2940360,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-17T21:05:11.000Z","date":"2020-12-15","kind":"grant","acquired":true,"shares":2199,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer.  The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"825 shares subject to the stock option were vested as of the date of acquisition, 46 shares shall vest on January 1, 2021, and 1,328 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date."}],"balance_after":2199,"derivative":{"exercise_price":42.8,"expiration_date":"2030-09-29","underlying":"Common Stock","underlying_shares":2199},"source":{"system":"sec-edgar","filing":"0000899243-20-034282","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320034282/doc4.xml","form_type":"4"}},{"id":2940359,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-17T21:05:11.000Z","date":"2020-12-15","kind":"grant","acquired":true,"shares":3137,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer.  The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1,177 shares subject to the stock option were vested as of the date of acquisition, 65 shares shall vest on January 1, 2021, and 1,895 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date."}],"balance_after":3137,"derivative":{"exercise_price":3.07,"expiration_date":"2030-07-20","underlying":"Common Stock","underlying_shares":3137},"source":{"system":"sec-edgar","filing":"0000899243-20-034282","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320034282/doc4.xml","form_type":"4"}},{"id":2940358,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-17T21:05:11.000Z","date":"2020-12-15","kind":"grant","acquired":true,"shares":4456,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer.  The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1,671 shares subject to the stock option were vested as of the date of acquisition, 93 shares shall vest on January 1, 2021, and 2,692 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date."}],"balance_after":4456,"derivative":{"exercise_price":3.07,"expiration_date":"2030-04-01","underlying":"Common Stock","underlying_shares":4456},"source":{"system":"sec-edgar","filing":"0000899243-20-034282","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320034282/doc4.xml","form_type":"4"}},{"id":2961015,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-02T21:17:12.000Z","date":"2020-12-01","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020."}],"balance_after":8282,"derivative":{"exercise_price":1.05,"exercise_date":"2020-05-19","expiration_date":"2029-09-24","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-20-032507","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320032507/doc4.xml","form_type":"4"}},{"id":2961014,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-12-02T21:17:12.000Z","date":"2020-12-01","kind":"sale","acquired":false,"shares":6972,"price":51.6937,"value":360408.4764,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold from $51.41 to $52.36 per share."}],"balance_after":274211,"source":{"system":"sec-edgar","filing":"0000899243-20-032507","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320032507/doc4.xml","form_type":"4"}},{"id":2961013,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-12-02T21:17:12.000Z","date":"2020-12-01","kind":"sale","acquired":false,"shares":3028,"price":51.1214,"value":154795.5992,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $50.41 to $51.40 per share.  The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3."}],"balance_after":281183,"source":{"system":"sec-edgar","filing":"0000899243-20-032507","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320032507/doc4.xml","form_type":"4"}},{"id":2961012,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-12-02T21:17:12.000Z","date":"2020-12-01","kind":"exercise","acquired":true,"shares":10000,"price":1.05,"value":10500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020."}],"balance_after":284211,"source":{"system":"sec-edgar","filing":"0000899243-20-032507","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320032507/doc4.xml","form_type":"4"}},{"id":2961011,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-12-02T21:05:09.000Z","date":"2020-06-03","kind":"sale","acquired":false,"shares":784,"price":30.0364,"value":23548.5376,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $30.00 to $30.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":261399,"source":{"system":"sec-edgar","filing":"0000899243-20-032503","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320032503/doc4.xml","form_type":"4"}},{"id":2975450,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2020-11-19T00:43:50.000Z","date":"2020-11-16","kind":"exercise","acquired":false,"shares":12813,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date.  6.25% of the RSUs vested on August 16, 2020 and November 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date.  6.25% of the RSUs vested on August 16, 2020 and November 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date."}],"balance_after":179375,"derivative":{"underlying":"Common Stock","underlying_shares":12813},"source":{"system":"sec-edgar","filing":"0000899243-20-031557","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320031557/doc4.xml","form_type":"4"}},{"id":2975449,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-19T00:43:50.000Z","date":"2020-11-16","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020."}],"balance_after":18282,"derivative":{"exercise_price":1.05,"exercise_date":"2020-05-19","expiration_date":"2029-09-24","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-20-031557","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320031557/doc4.xml","form_type":"4"}},{"id":2975448,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-11-19T00:43:50.000Z","date":"2020-11-16","kind":"tax_withholding","acquired":false,"shares":6353,"price":44.33,"value":281628.49,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 12,813 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":274211,"source":{"system":"sec-edgar","filing":"0000899243-20-031557","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320031557/doc4.xml","form_type":"4"}},{"id":2975447,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-11-19T00:43:50.000Z","date":"2020-11-16","kind":"exercise","acquired":true,"shares":12813,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":280564,"source":{"system":"sec-edgar","filing":"0000899243-20-031557","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320031557/doc4.xml","form_type":"4"}},{"id":2975446,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-11-19T00:43:50.000Z","date":"2020-11-16","kind":"sale","acquired":false,"shares":10000,"price":45,"value":450000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020."}],"balance_after":267751,"source":{"system":"sec-edgar","filing":"0000899243-20-031557","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320031557/doc4.xml","form_type":"4"}},{"id":2975445,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-11-19T00:43:50.000Z","date":"2020-11-16","kind":"exercise","acquired":true,"shares":10000,"price":1.05,"value":10500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020."}],"balance_after":277751,"source":{"system":"sec-edgar","filing":"0000899243-20-031557","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320031557/doc4.xml","form_type":"4"}},{"id":2994941,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-03T21:05:09.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020."}],"balance_after":28282,"derivative":{"exercise_price":1.05,"exercise_date":"2020-05-19","expiration_date":"2029-09-24","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-20-030214","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320030214/doc4.xml","form_type":"4"}},{"id":2994940,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-11-03T21:05:09.000Z","date":"2020-11-02","kind":"sale","acquired":false,"shares":500,"price":38.9156,"value":19457.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold from $38.86 to $38.97 per share."}],"balance_after":267751,"source":{"system":"sec-edgar","filing":"0000899243-20-030214","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320030214/doc4.xml","form_type":"4"}},{"id":2994939,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-11-03T21:05:09.000Z","date":"2020-11-02","kind":"sale","acquired":false,"shares":9500,"price":38.3263,"value":364099.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $37.80 to $38.79 per share.  The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3."}],"balance_after":268251,"source":{"system":"sec-edgar","filing":"0000899243-20-030214","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320030214/doc4.xml","form_type":"4"}},{"id":2994938,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-11-03T21:05:09.000Z","date":"2020-11-02","kind":"exercise","acquired":true,"shares":10000,"price":1.05,"value":10500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020."}],"balance_after":277751,"source":{"system":"sec-edgar","filing":"0000899243-20-030214","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320030214/doc4.xml","form_type":"4"}},{"id":3013527,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-05T20:05:33.000Z","date":"2020-10-01","kind":"exercise","acquired":false,"shares":6745,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020."}],"balance_after":38282,"derivative":{"exercise_price":1.05,"exercise_date":"2020-05-19","expiration_date":"2029-09-24","underlying":"Common Stock","underlying_shares":6745},"source":{"system":"sec-edgar","filing":"0000899243-20-027232","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320027232/doc4.xml","form_type":"4"}},{"id":3013526,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-05T20:05:33.000Z","date":"2020-10-01","kind":"exercise","acquired":false,"shares":1019,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020."}],"balance_after":0,"derivative":{"exercise_price":0.28,"exercise_date":"2020-05-19","expiration_date":"2028-05-07","underlying":"Common Stock","underlying_shares":1019},"source":{"system":"sec-edgar","filing":"0000899243-20-027232","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320027232/doc4.xml","form_type":"4"}},{"id":3013525,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-05T20:05:33.000Z","date":"2020-10-01","kind":"exercise","acquired":false,"shares":2236,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020."}],"balance_after":0,"derivative":{"exercise_price":0.28,"exercise_date":"2020-05-19","expiration_date":"2027-11-13","underlying":"Common Stock","underlying_shares":2236},"source":{"system":"sec-edgar","filing":"0000899243-20-027232","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320027232/doc4.xml","form_type":"4"}},{"id":3013524,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-10-05T20:05:33.000Z","date":"2020-10-01","kind":"sale","acquired":false,"shares":5505,"price":39.2822,"value":216248.511,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold from $38.81 to $39.71 per share."}],"balance_after":267751,"source":{"system":"sec-edgar","filing":"0000899243-20-027232","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320027232/doc4.xml","form_type":"4"}},{"id":3013523,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-10-05T20:05:33.000Z","date":"2020-10-01","kind":"sale","acquired":false,"shares":4495,"price":38.2855,"value":172093.3225,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $37.74 to $38.72 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3."}],"balance_after":273256,"source":{"system":"sec-edgar","filing":"0000899243-20-027232","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320027232/doc4.xml","form_type":"4"}},{"id":3013522,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-10-05T20:05:33.000Z","date":"2020-10-01","kind":"exercise","acquired":true,"shares":6745,"price":1.05,"value":7082.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020."}],"balance_after":277751,"source":{"system":"sec-edgar","filing":"0000899243-20-027232","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320027232/doc4.xml","form_type":"4"}},{"id":3013521,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-10-05T20:05:33.000Z","date":"2020-10-01","kind":"exercise","acquired":true,"shares":3255,"price":0.28,"value":911.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020."}],"balance_after":271006,"source":{"system":"sec-edgar","filing":"0000899243-20-027232","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320027232/doc4.xml","form_type":"4"}},{"id":3025064,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-22T23:05:53.000Z","date":"2020-09-18","kind":"exercise","acquired":false,"shares":5099,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020."}],"balance_after":2236,"derivative":{"exercise_price":0.28,"exercise_date":"2020-05-19","expiration_date":"2027-11-13","underlying":"Common Stock","underlying_shares":5099},"source":{"system":"sec-edgar","filing":"0000899243-20-025961","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320025961/doc4.xml","form_type":"4"}},{"id":3025063,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-22T23:05:53.000Z","date":"2020-09-18","kind":"exercise","acquired":false,"shares":4901,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020."}],"balance_after":4586,"derivative":{"exercise_price":0.16,"exercise_date":"2020-05-19","expiration_date":"2028-08-26","underlying":"Common Stock","underlying_shares":4901},"source":{"system":"sec-edgar","filing":"0000899243-20-025961","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320025961/doc4.xml","form_type":"4"}}],"next_cursor":"2020-09-22T23:05:53.000000Z,3025063"}